HUP9802078A3 - Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection - Google Patents
Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejectionInfo
- Publication number
- HUP9802078A3 HUP9802078A3 HU9802078A HUP9802078A HUP9802078A3 HU P9802078 A3 HUP9802078 A3 HU P9802078A3 HU 9802078 A HU9802078 A HU 9802078A HU P9802078 A HUP9802078 A HU P9802078A HU P9802078 A3 HUP9802078 A3 HU P9802078A3
- Authority
- HU
- Hungary
- Prior art keywords
- lck
- autoimmune diseases
- specific compounds
- allograft rejection
- treat autoimmune
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38638195A | 1995-02-10 | 1995-02-10 | |
| US40022095A | 1995-03-07 | 1995-03-07 | |
| US49735795A | 1995-06-30 | 1995-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9802078A2 HUP9802078A2 (hu) | 1998-12-28 |
| HUP9802078A3 true HUP9802078A3 (en) | 1999-04-28 |
Family
ID=27409758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9802078A HUP9802078A3 (en) | 1995-02-10 | 1996-02-09 | Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP0809490A4 (hu) |
| JP (2) | JPH10513474A (hu) |
| KR (1) | KR19980702115A (hu) |
| AU (1) | AU4923796A (hu) |
| BR (1) | BR9607614A (hu) |
| CA (1) | CA2212645A1 (hu) |
| FI (1) | FI973259A (hu) |
| HU (1) | HUP9802078A3 (hu) |
| NO (1) | NO973659L (hu) |
| WO (1) | WO1996024343A1 (hu) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922697A (en) * | 1996-10-02 | 1999-07-13 | Warner-Lambert Company | Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins |
| EP1608629A1 (en) | 2003-03-24 | 2005-12-28 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| WO2005090317A1 (en) | 2004-03-23 | 2005-09-29 | F.Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5136093A (en) * | 1992-09-25 | 1994-04-26 | Warner-Lambert Company | Peptide antagonists of sh2 binding and therapeutic uses thereof |
| US5580979A (en) * | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
| US5710129A (en) * | 1995-02-23 | 1998-01-20 | Ariad Pharmaceuticals, Inc. | Inhibitors of SH2-mediated processes |
-
1996
- 1996-02-09 AU AU49237/96A patent/AU4923796A/en not_active Abandoned
- 1996-02-09 KR KR1019970705510A patent/KR19980702115A/ko not_active Application Discontinuation
- 1996-02-09 BR BR9607614A patent/BR9607614A/pt not_active Application Discontinuation
- 1996-02-09 WO PCT/US1996/001964 patent/WO1996024343A1/en not_active Application Discontinuation
- 1996-02-09 HU HU9802078A patent/HUP9802078A3/hu unknown
- 1996-02-09 JP JP8524486A patent/JPH10513474A/ja active Pending
- 1996-02-09 CA CA002212645A patent/CA2212645A1/en not_active Abandoned
- 1996-02-09 EP EP96905494A patent/EP0809490A4/en not_active Withdrawn
- 1996-02-12 JP JP8524493A patent/JPH10513564A/ja active Pending
- 1996-02-12 EP EP96906615A patent/EP0811159A1/en not_active Withdrawn
-
1997
- 1997-08-07 FI FI973259A patent/FI973259A/fi unknown
- 1997-08-08 NO NO973659A patent/NO973659L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2212645A1 (en) | 1996-08-15 |
| NO973659L (no) | 1997-10-08 |
| FI973259A (fi) | 1997-10-08 |
| FI973259A0 (fi) | 1997-08-07 |
| HUP9802078A2 (hu) | 1998-12-28 |
| JPH10513474A (ja) | 1998-12-22 |
| EP0809490A4 (en) | 1999-10-20 |
| EP0809490A1 (en) | 1997-12-03 |
| BR9607614A (pt) | 1998-06-09 |
| JPH10513564A (ja) | 1998-12-22 |
| EP0811159A1 (en) | 1997-12-10 |
| WO1996024343A1 (en) | 1996-08-15 |
| AU4923796A (en) | 1996-08-27 |
| KR19980702115A (ko) | 1998-07-15 |
| NO973659D0 (no) | 1997-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL327312A1 (en) | Tricyclic amides useful in inhibiting action of g protecin and in treatment of poliferation-type diseases | |
| AU4859296A (en) | Improved fiber filter and methods of use thereof | |
| IL123601A0 (en) | Use of epinastine for the treatment of pain | |
| GB9526560D0 (en) | Use of 2-Amino-Heterocycles | |
| IL115015A0 (en) | Methods of inhibiting demyelinating and desmyelinating diseases | |
| GB9324773D0 (en) | Treatment of cellulose | |
| GB2284205B (en) | Treatment of agricultural waste | |
| EG21286A (en) | Blends of organosillane compounds and their use | |
| NZ300198A (en) | Preparation of n-arylhydroxylamines and n-hetarylhydroxylamines | |
| SG42329A1 (en) | Use of phenylcyclohexylcarboxamides | |
| HUP9802078A3 (en) | Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection | |
| GB9502136D0 (en) | Treatment of waste | |
| GB2283485B (en) | Treatment of sludge | |
| ZA961318B (en) | Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection | |
| PL322002A1 (en) | Variants of human dnase i | |
| EP0833641A4 (en) | TREATMENT AND PREVENTION OF PROSTATE DISEASES | |
| AU2845897A (en) | Photosensitive elements and their process of use | |
| GB2265366B (en) | Treatment of waste | |
| GB9516572D0 (en) | Prevention and/or treatment of disease | |
| GB9424333D0 (en) | Treatment of aqueous effluents containing fats and oils | |
| GB9526317D0 (en) | Improvements in and relating to treatment of effluent sludge | |
| AU3163795A (en) | Treatment of autoimmune diseases | |
| AU6852896A (en) | Diagnosis and treatment of neurological disease | |
| EP0444931A3 (en) | Use of 3-oxygermylpropionic acid to treat and prevent diabetes-dependent autoimmune diseases | |
| GB9504444D0 (en) | Treatment of eczema |